BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew Sells 10,589 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 10,589 shares of the business’s stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $22.66, for a total transaction of $239,946.74. Following the completion of the sale, the executive vice president now owns 309,576 shares of the company’s stock, valued at approximately $7,014,992.16. This represents a 3.31 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

BioLife Solutions Stock Performance

BLFS opened at $20.88 on Friday. The company has a market cap of $981.36 million, a P/E ratio of -19.70 and a beta of 2.04. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The firm’s 50-day moving average price is $25.87 and its 200-day moving average price is $25.50. BioLife Solutions, Inc. has a 52-week low of $14.84 and a 52-week high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The business had revenue of $22.71 million for the quarter, compared to analyst estimates of $21.73 million. During the same quarter in the prior year, the business posted ($0.21) EPS. As a group, equities analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BLFS has been the subject of a number of recent research reports. KeyCorp boosted their price objective on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. HC Wainwright boosted their price target on BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. StockNews.com lowered BioLife Solutions from a “hold” rating to a “sell” rating in a research note on Monday, March 31st. Northland Securities increased their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research report on Wednesday, January 8th. Finally, Benchmark reaffirmed a “buy” rating and issued a $30.00 price objective on shares of BioLife Solutions in a research report on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.17.

Hedge Funds Weigh In On BioLife Solutions

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Intech Investment Management LLC purchased a new stake in BioLife Solutions during the 3rd quarter valued at about $255,000. Charles Schwab Investment Management Inc. lifted its stake in BioLife Solutions by 3.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 319,959 shares of the medical equipment provider’s stock valued at $8,012,000 after acquiring an additional 9,750 shares during the period. Cerity Partners LLC boosted its holdings in shares of BioLife Solutions by 6.6% in the 3rd quarter. Cerity Partners LLC now owns 44,914 shares of the medical equipment provider’s stock valued at $1,125,000 after acquiring an additional 2,776 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of BioLife Solutions by 40.8% in the third quarter. The Manufacturers Life Insurance Company now owns 19,463 shares of the medical equipment provider’s stock worth $487,000 after acquiring an additional 5,638 shares during the period. Finally, FMR LLC raised its holdings in shares of BioLife Solutions by 470.6% during the third quarter. FMR LLC now owns 13,317 shares of the medical equipment provider’s stock worth $333,000 after purchasing an additional 10,983 shares during the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.